Table 1.
PSA and Tumor Volume (mean ± SEM) of orthotopically grown LNCaP tumors at 6 weeks following AD + Edelfosine treatments (n = 9 -13).
| Group | TV (mm3) | PSA (ng/ml) | % of mice with TV<100 mm3 (no./total) | % of mice with PSA <25 ng/ml (no./total) | % combined (no./total) | *TV doubling time (weeks) | *PSA doubling time (weeks) |
|---|---|---|---|---|---|---|---|
| PBS | 314 ± 52 | 91 ± 7 | 10% (1/10) | 10% (1/10) | 10% (1/10) | 2.77 ± 0.4 | 2.40 ± 0.2 |
| Edel (20 mg) | 192 ± 63† | 39 ± 12† | 60% (6/10)† | 50% (5/10)† | 50% (5/10)† | 6.49 ± 1.3† | 5.83 ± 1.2† |
| PBS + AD | 112 ± 52 | 30 ± 12 | 80% (8/10) | 60% (6/10) | 60% (6/10) | 3.94 ± 1.1 | 3.51 ± 1.1 |
| Edel (20 mg) + AD | 15 ± 6†,‡ | 2 ± 1†,‡ | 100% (11/11) | 100% (11/11)†,‡ | 100% (11/11)†,‡ | 7.63±1.0† | 7.94 ± 1.1† |
Tumor parameters were calculated by kinetic modeling of longitudinal data from PSA and tumor volume. PSA and TV values for fast growing tumors are truncated at 100 ng/ml and/or 500 mm3, respectively.
Tumor doubling times were calculated from fitted data for mice where TV and PSA exhibit an upward trend after treatment. For the rest of the animals 10 weeks is assumed.
Statistically significant difference (p < 0.05), compared to the PBS group.
Statistically significant difference (p < 0.05), compared to all groups.
Abbreviations:
AD, androgen deprivation; PSA, prostate specific antigen; TV, tumor volume; PBS, phosphate buffered saline; Edel – edelfosine.